JP2009530235A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530235A5
JP2009530235A5 JP2008558610A JP2008558610A JP2009530235A5 JP 2009530235 A5 JP2009530235 A5 JP 2009530235A5 JP 2008558610 A JP2008558610 A JP 2008558610A JP 2008558610 A JP2008558610 A JP 2008558610A JP 2009530235 A5 JP2009530235 A5 JP 2009530235A5
Authority
JP
Japan
Prior art keywords
composition
stem cell
administered
neural stem
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2007/000427 external-priority patent/WO2007106987A1/en
Publication of JP2009530235A publication Critical patent/JP2009530235A/ja
Publication of JP2009530235A5 publication Critical patent/JP2009530235A5/ja
Pending legal-status Critical Current

Links

JP2008558610A 2006-03-17 2007-03-16 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン Pending JP2009530235A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78350006P 2006-03-17 2006-03-17
US78913206P 2006-04-05 2006-04-05
US86266906P 2006-10-24 2006-10-24
PCT/CA2007/000427 WO2007106987A1 (en) 2006-03-17 2007-03-16 Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010056766A Division JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン

Publications (2)

Publication Number Publication Date
JP2009530235A JP2009530235A (ja) 2009-08-27
JP2009530235A5 true JP2009530235A5 (cg-RX-API-DMAC7.html) 2010-04-30

Family

ID=38521972

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008558609A Pending JP2009530234A (ja) 2006-03-17 2007-03-16 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン
JP2008558610A Pending JP2009530235A (ja) 2006-03-17 2007-03-16 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2010056766A Pending JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2010056764A Pending JP2010138202A (ja) 2006-03-17 2010-03-12 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008558609A Pending JP2009530234A (ja) 2006-03-17 2007-03-16 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010056766A Pending JP2010138203A (ja) 2006-03-17 2010-03-12 神経幹細胞増殖剤および神経幹細胞分化剤の連続投与レジメン
JP2010056764A Pending JP2010138202A (ja) 2006-03-17 2010-03-12 神経変性疾患の治療のためのlhまたはhcg、およびepoについての投与レジメン

Country Status (8)

Country Link
US (3) US8143220B2 (cg-RX-API-DMAC7.html)
EP (2) EP2004212A4 (cg-RX-API-DMAC7.html)
JP (4) JP2009530234A (cg-RX-API-DMAC7.html)
KR (2) KR20080103108A (cg-RX-API-DMAC7.html)
AU (2) AU2007229300B2 (cg-RX-API-DMAC7.html)
CA (2) CA2644116A1 (cg-RX-API-DMAC7.html)
IL (2) IL193856A0 (cg-RX-API-DMAC7.html)
WO (2) WO2007106986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
ES2392282T3 (es) 2004-02-13 2012-12-07 Stem Cell Therapeutics Corp. Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
WO2007106986A1 (en) 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
CN101517883B (zh) * 2006-09-25 2012-07-04 国立大学法人东京农工大学 超声波操作装置和微细管内检查系统
JP2011505335A (ja) * 2007-09-11 2011-02-24 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのTRP−6−トリプトレリンおよびD−Leu6−ロイプロリドの使用
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
MX2011009967A (es) * 2009-03-26 2012-01-25 Ford Henry Health System Composiciones y metodo para mejorar el resultado neurologico despues de daño neural y enfermedad neurodegenerativa.
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
US20120265129A1 (en) 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
WO2012156968A2 (en) * 2011-05-19 2012-11-22 Ariel - University Research And Development Company, Ltd. Use of mesenchymal stem cells for the improvement of affective and cognitive function
WO2013112002A1 (ko) * 2012-01-27 2013-08-01 의료법인 성광의료재단 뇌 손상 증세의 경감 또는 완화에 대한 바이오마커
BR112015008753A2 (pt) 2012-10-18 2017-07-04 Neuralight Hd Llc tratamento de depressão e ptsd
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
WO2017179225A1 (ja) * 2016-04-13 2017-10-19 味の素株式会社 加齢に伴う身体機能低下もしくは身体機能障害、または加齢に伴う精神機能低下もしくは精神機能障害の抑制または改善用組成物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4902680A (en) 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1990005185A1 (fr) 1988-11-07 1990-05-17 L'universite De L'etat A Liege Hormone de croissance humaine modifiee
US5128242A (en) 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5198542A (en) 1989-06-20 1993-03-30 Takeda Chemical Industries, Inc. Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
EP0467279A3 (en) 1990-07-18 1992-08-05 Takeda Chemical Industries, Ltd. Polypeptides having c-amp producing activity
US5521069A (en) 1990-08-10 1996-05-28 Takeda Chemical Industries, Ltd. Genomic DNA exons having exons encoding human pituitary adenylate cyclase activity peptide with 38 amino acids residues(PACAP38) and a promoter thereof
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
US5723115A (en) 1991-05-02 1998-03-03 W. Alton Jones Cell Science Center, Inc. Inhibition of adipose tissue development and obesity
ATE196548T1 (de) 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
FI935929L (fi) 1991-07-08 1994-02-02 Neurospheres Ltd Ny vaext regulerande faktor i stamcellen som foermaor foeroeka in vitro
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
AU2489992A (en) 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5623050A (en) 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
US5253648A (en) 1991-10-11 1993-10-19 Spacelabs Medical, Inc. Method and apparatus for excluding artifacts from automatic blood pressure measurements
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
ATE221117T1 (de) 1992-10-16 2002-08-15 Neurospheres Holdings Ltd Remyelination unter verwendung von neuronalen stammzellen
ATE483795T1 (de) 1992-10-28 2010-10-15 Neurospheres Holdings Ltd Biologische faktoren und neuronale stammzellen
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
DE69431993T2 (de) 1993-11-09 2003-11-27 Neurospheres Holding Ltd., Calgary In situ modifikation und manipulation von stammzellen des zentralen nervensystems
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US6399316B1 (en) 1994-02-25 2002-06-04 Takeda Chemical Industries, Ltd. PACAP receptor protein, method for preparing said protein, and use thereof
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6239105B1 (en) 1994-03-31 2001-05-29 Barbara A. Brewitt Homeopathic preparations of purified growth hormone
WO1995029690A1 (en) 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5547143A (en) * 1994-08-24 1996-08-20 Alliedsignal Inc. Seat belt retractor with integrated load limiter
US6680295B1 (en) 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
JPH10505863A (ja) 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
FI971956L (fi) 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
AU6163196A (en) 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5547993A (en) 1995-10-24 1996-08-20 Mitsubishi Chemical Corporation Therapeutic agent for glaucoma
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
AU3492497A (en) 1996-06-21 1998-01-07 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
IT1284876B1 (it) 1996-08-07 1998-05-22 Applied Research Systems Hcg come inibitore della collagenasi
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
WO1999015191A2 (en) 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
EP1032388A4 (en) 1997-10-31 2002-10-02 Smithkline Beecham Corp NEW METAL COMPLEXES
TW445295B (en) 1997-12-31 2001-07-11 Shiu Li Wei Expression vector pcDNA3.1-HC for human erythropoietin, BHK-21 host cell line transformed therewith, and production of human erythropoietin using the transformed cell
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6242563B1 (en) 1998-07-20 2001-06-05 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Peptide analogues
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
FR2794473B1 (fr) 1999-06-03 2003-09-26 Centre Nat Rech Scient Procede de multiplication de cellules souches
US6618698B1 (en) 1999-08-12 2003-09-09 Quickturn Design Systems, Inc. Clustered processors in an emulation engine
US6395546B1 (en) 2000-02-01 2002-05-28 Neurogeneration, Inc. Generation of dopaminergic neurons from human nervous system stem cells
KR100358754B1 (ko) * 2000-02-14 2002-11-07 대한민국 인간의 조혈촉진제 생산을 위한 형질전환 돼지를 생산하는방법 및 그 형질전환 돼지
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
AU7107301A (en) 2000-07-18 2002-01-30 Nichimo Co. Ltd. Stem cell reinforcing material
ES2315350T3 (es) 2001-01-12 2009-04-01 Waratah Pharmaceuticals Inc. Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
US6740163B1 (en) 2001-06-15 2004-05-25 Seagate Technology Llc Photoresist recirculation and viscosity control for dip coating applications
WO2002102988A2 (en) 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
EP1415463A4 (en) 2001-07-19 2005-10-12 Thomson Licensing Robust reception of digital broadcast transmission
CA2364095C (en) 2001-07-20 2011-07-12 Neurostasis, Inc Production of radial glial cells
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
EP1430114B1 (en) * 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
AR036402A1 (es) 2001-09-18 2004-09-08 Stem Cell Therapeutics Inc Efecto de la hormona de crecimiento y de igf-1 sobre celulas madre neuronales.
ITPR20010072A1 (it) 2001-10-26 2003-04-26 Firaco Srl Apparato e procedimento di sicurezza per veicoli di trasporto, in particolare aeromobili.
WO2003092716A2 (en) 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
WO2004011497A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
WO2004011021A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US20050009847A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
JP2006521405A (ja) 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用
US20070111932A1 (en) 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
ES2392282T3 (es) 2004-02-13 2012-12-07 Stem Cell Therapeutics Corp. Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis
AU2005291810B2 (en) * 2004-10-07 2011-12-08 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
WO2007106986A1 (en) 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
WO2008077027A2 (en) 2006-12-18 2008-06-26 Case Western Reserve University Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders
WO2008077085A1 (en) 2006-12-19 2008-06-26 Case Western Reserve University Brain-derived gonadotropins and cognition
US20080286234A1 (en) 2007-05-15 2008-11-20 Eyink Daniel A Method for treating demyelinating diseases

Similar Documents

Publication Publication Date Title
JP2009530234A5 (cg-RX-API-DMAC7.html)
Spagnolo et al. The management of patients with idiopathic pulmonary fibrosis
Panicker et al. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management
Aujla et al. TH17 cells in asthma and inflammation
Park et al. Human umbilical cord blood cell grafts for brain ischemia
Wang et al. Cell therapy with autologous mesenchymal stem cells—how the disease process impacts clinical considerations
JP2014530821A5 (cg-RX-API-DMAC7.html)
D’Souza et al. Targeting the cholinergic system to develop a novel therapy for Huntington’s disease
EP2478901A3 (en) Neurogenic compounds
Dursun et al. Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study
JP2010518164A5 (cg-RX-API-DMAC7.html)
JP2006131623A (ja) 薬剤
Tae et al. Neuronal injury and tumor necrosis factor-alpha immunoreactivity in the rat hippocampus in the early period of asphyxia-induced cardiac arrest under normothermia
CN117617181B (zh) 一种系统性红斑狼疮小鼠模型的构建方法和应用
US9682078B2 (en) Compositions and methods for tissue engineering and cell based therapies
JP2014129405A5 (cg-RX-API-DMAC7.html)
CN109562145B (zh) 含胰岛素样生长因子-2的药物组合物及其应用
Liu et al. The therapeutic effect of exosomes in type 2 diabetes mellitus and its complications
Xiong et al. Neuroprotection of erythropoietin and methylprednisolone against spinal cord ischemia-reperfusion injury
CN119424478A (zh) 用于多聚谷氨酰胺(polyq)疾病的治疗
Lee et al. Human umbilical cord blood-derived mesenchymal stem cells improve neurological abnormalities of Niemann-Pick type C mouse by modulation of neuroinflammatory condition
JP2012502105A5 (cg-RX-API-DMAC7.html)
CN1935157B (zh) 一种用于治疗皮肤病的麦饭石乳膏及其制备方法
Pocock et al. An open-label, prospective study evaluating the clinical and immunological effects of higher dose granulocyte colony–stimulating factor in ALS
Linden et al. Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant: a case report